Your Dose of Cannabis Education

Your Dose of Cannabis Education

Only have a minute but want to Learn something every day? Sign up to receive Your Dose of Cannabis Education, bringing featured content from our course library right to your inbox each day.

Your Dose of Cannabis Education is based on data from the studies and reviews published in the current peer-reviewed medical journals. Whether you are a healthcare provider, patient, caregiver, an individual working in the healthcare sector, or just a curious person, you can benefit from Your Dose of Cannabis Education

Wake up every morning and get your dose of unbiased evidence-based cannabis education!

Bennabis Health

We’re making medical cannabis
more affordable and
understandable!

Use code BENNABISHEALTH to save 20% on any CME Course.

Visit the Bennabis Health website.

2024-04-19
What are some of the more common reasons dermatologists recommend cannabinoid-based medicines?
According to the results of a survey of 145 dermatologists, 91 % of dermatologists were in support of medical cannabis use and 13.8 % have recommended it for a dermatologic condition. Atopic dermatitis (45 %) and psoriasis (40 %) were the most common. The most common form of administration was topical (75 %). The main reasons for not recommending medical cannabis were limited knowledge (56 %) and lack of experience (48 %).
Perceptions and recommendation behaviors of dermatologists for medical cannabis: A pilot survey. SamuelYeroushalmiaKamariaNelsonaAndrewSparksbAdamFriedmana. https://pubmed.ncbi.nlm.nih.gov/33220620/
2024-04-18
What is the half life of CBD? How does it compare to the half life of THC?
The half life of CBD is 18-32 hours, which is similar to the half life of THC of 20-30 hours. Both CBD and THC are distributed to fatty tissues and highly perfused organs such as brain, heart, lung, and liver.
Medical Marijuana, Recreational Cannabis, and Cardiovascular Health: A Scientific Statement From the American Heart Association Robert L. Page II , Larry A. Allen , Robert A. Kloner , Colin R. Carriker , Catherine Martel , Alanna A. Morris , Mariann R. Piano , Jamal S. Rana , Jorge F. Saucedo , … See all authors Originally published5 Aug 2020. https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000883
2024-04-17
Does the endocannabinoid system play a role in the modulation of associative fear learning?
Yes. The endocannabinoid system is involved with learned fear and anxiety. For example, CB1 activation at the basolateral amygdala (BLA) modulates associative fear learning. (The BLA is involved with information storage and the formation of conditioned fear responses to previously neutral stimuli- neutral stimuli are paired with aversive stimuli.) Also, CB1 receptors in the area of the prefrontal networks modulate fear expression and fear extinction.
Anthony Murkar, Joseph De Koninck, Zul Merali, Cannabinoids: Revealing their complexity and role in central networks of fear and anxiety, Neuroscience & Biobehavioral Reviews, Volume 131, 2021, Pages 30-46, ISSN 0149-7634, https://www.sciencedirect.com/science/article/abs/pii/S0149763421003845?via%3Dihub
2024-04-16
What are the mechanisms in which THC and CBD impact pain sensation?
According to a British Medical Journal (BMJ) article, "THC inhibits glutamate and 5-hydroxytryptamine release and increases dopamine secretion. CBD enhances adenosine receptor signaling, and decreases reactive oxygen species, tumour necrosis factor, and T cell proliferation, without the psychoactive effects of THC. The multifaceted analgesic and anti-inflammatory properties of cannabinoids may positively influence the perception of pain across different conditions."
Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. BMJ 2021;374:n2040 (Published 09 September 2021) https://doi.org/10.1136/bmj.n2040
2024-04-15
Can children with developmental and epileptic encephalopathies tolerate adjunctive cannabidiol (CBD) transdermal gel, and is CBD gel associated with reduced seizure frequency?
According to a JAMA Open Network article, in a "nonrandomized controlled trial, CBD transdermal gel was well tolerated over 6.5 months of treatment, with 60% of patients experiencing a treatment-related adverse event, 96% of which were mild or moderate. A 43.5% reduction in seizure frequency was observed in focal impaired awareness seizures and tonic-clonic seizures." Also, the researchers stated that "Parents and caregivers noted improvements in social or interpersonal engagement and irritability; alertness, energy, and sleep; and cognition or concentration."
Scheffer IE, Hulihan J, Messenheimer J, et al. Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial. JAMA Netw Open. 2021;4(9):e2123930. doi:10.1001/jamanetworkopen.2021.23930 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2783716

Learn something every day in your feed…

Follow @The_Answer_Page

New to TheAnswerPage? There’s lots we’d like to share with you and we don’t want you to miss a thing! Be sure to register today for “Your Dose of Cannabis Education” emails where you’ll gain valuable insights in small doses that fit your schedule and also be provided direct access to the archived daily content.